-

Thermo Fisher Scientific’s Clinical Research Business Named Clinical Research Company of the Year for Third Consecutive Year

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London.

In addition to the business winning the highest honor again this year, 50 clinical researchers from the company were named finalists within all nine eligible team and individual competition categories.

“For the third year in a row, our colleagues have made their presence known by winning multiple recognitions, including the top title, in this highly regarded competition,” said Amber Lee, senior vice president, clinical operations, clinical research, Thermo Fisher Scientific. “The unwavering dedication, expertise and passion our colleagues put on display at the competition are the same qualities they apply every day to our customers’ vital research initiatives. We believe in sustaining a great culture and providing our colleagues with challenging opportunities for professional growth. This, in turn, supports our ability to recruit, develop and retain top talent to serve our customers.”

The business’ award-winning training and development programs, such as CRA Academy, are a key component in strengthening employees’ skills. The academy guides clinical research associates as they gain real-time work experience with effective training and formal academy-based learning. To date, more than 1,000 professionals have graduated from the program.

The Clinical Researcher of the Year Awards competition, hosted by PharmaTimes, consists of a rigorous series of assessments, including a three-stage competition, where participants give presentations before a panel of experienced industry judges. The event was created to provide clinical research professionals an opportunity to benchmark their skills against their peers in a program of competency-based exercises developed through cross-industry collaboration.

Colleagues from Thermo Fisher’s clinical research business won gold in the Aspiring Clinical Research Associate (CRA) category, silver in the CRA category, silver and bronze in the In-House CRA category, silver in the Team Leader category, bronze in the Clinical Team category, gold and bronze in the Start Up-Singles category, as well as gold and silver in the Start-Up Team category.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media Contact Information:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
Thermo Fisher Scientific’s PPD clinical research business has been named Clinical Research Company of the Year for the third consecutive year.
Release Versions

Contacts

Media Contact Information:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the Gibco™ VaxEvo™ CD 293 Medium, a chemically defined and animal origin-free medium designed to support suspension HEK293 cell growth and high-titer adenovirus production. Available in liquid and AGT™ formats, the medium is designed to support vaccine developers from early process development through scale-up and manufacturing. As suspension-based HEK293 workflows evolve to support s...

Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will participate in a fireside chat hosted by UBS on Thursday, November 19th, at 8:30 a.m. (ET). The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, wi...

Thermo Fisher Scientific Continues Semiconductor Lab-to-Fab Innovation with Multiple Installations of Optis™ FIB-SEM

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has completed multiple installations of the Thermo Scientific Optis™ focused ion beam-scanning electron microscope (FIB-SEM). As semiconductor manufacturers develop increasingly complex chips that power everything from smart devices to healthcare technologies, they need faster, more accurate and consistent data to drive innovation. The system combines automated sample pre...
Back to Newsroom